A Diversified Portfolio Driven by OmniAntigen™
From cell therapies to systemic nanomedicines, Novastra is advancing a pipeline designed to address the full continuum of solid tumor resistance.
OAP-101
Flagship Program
Targeting last-line, checkpoint-refractory solid tumors. OAP-101 acts as a "Universal Combination Backbone." It is designed to restore sensitivity not only to PD-1 blockade but also to empower Bispecific Antibodies and CAR-T therapies by generating de novo T-cells and facilitating their infiltration into the tumor nest.
OAP-102
Pediatric Focus
A specialized formulation for High-Risk Neuroblastoma. Addressing a critical unmet need in pediatric oncology, this program is positioned for Rare Pediatric Disease (RPD) designation. The RPD-PRV status for OAP-102 is a corporate assessment based on current FDA criteria for Rare Pediatric Disease Designation. Formal designation is subject to FDA review and approval.
OAP-201
Systemic Expansion
Next-generation XIRT-Exosomes. By leveraging the natural trafficking properties of exosomes engineered with our bio-based nanotechnology, this asset is designed for intravenous delivery to treat distant metastases.
OAP-301
Surgical Solution
A bio-active scaffold designed to eliminate Microscopic
Residual Disease (MRD) in the post-surgical setting,
acting as a preventative shield against recurrence.